{"transactions":[{"id":943141,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":69762,"kind":"person","name":"Davis Blaine","position":1,"cik":"0001802188","reported_name":"Davis Blaine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common  Stock","published_at":"2026-01-08T21:19:50.000Z","date":"2026-01-06","kind":"sale","planned":false,"acquired":false,"shares":10591,"price":6.8197,"value":72227.4427,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees."}],"balance_after":121220,"source":{"system":"sec-edgar","filing":"0001453687-26-000045","document":"wk-form4_1767907186.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368726000045/wk-form4_1767907186.xml","form_type":"4"}},{"id":946579,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":69762,"kind":"person","name":"Davis Blaine","position":1,"cik":"0001802188","reported_name":"Davis Blaine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-06T21:18:46.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":109000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests as to 25% on January 2, 2027. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter."}],"balance_after":109000,"derivative":{"exercise_price":6.76,"expiration_date":"2036-01-01","underlying":"Common  Stock","underlying_shares":109000},"source":{"system":"sec-edgar","filing":"0001453687-26-000033","document":"wk-form4_1767734322.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368726000033/wk-form4_1767734322.xml","form_type":"4"}},{"id":946578,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":69762,"kind":"person","name":"Davis Blaine","position":1,"cik":"0001802188","reported_name":"Davis Blaine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common  Stock","published_at":"2026-01-06T21:18:46.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":37000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2027. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2030."}],"balance_after":131811,"source":{"system":"sec-edgar","filing":"0001453687-26-000033","document":"wk-form4_1767734322.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368726000033/wk-form4_1767734322.xml","form_type":"4"}},{"id":1307904,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":69762,"kind":"person","name":"Davis Blaine","position":1,"cik":"0001802188","reported_name":"Davis Blaine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common  Stock","published_at":"2025-01-08T01:04:49.000Z","date":"2025-01-06","kind":"sale","planned":false,"acquired":false,"shares":4028,"price":16.8322,"value":67800.1016,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees."}],"balance_after":94811,"source":{"system":"sec-edgar","filing":"0001453687-25-000035","document":"wk-form4_1736298282.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368725000035/wk-form4_1736298282.xml","form_type":"4"}},{"id":1307903,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":69762,"kind":"person","name":"Davis Blaine","position":1,"cik":"0001802188","reported_name":"Davis Blaine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common  Stock","published_at":"2025-01-08T01:04:49.000Z","date":"2025-01-03","kind":"sale","planned":false,"acquired":false,"shares":3961,"price":16.7219,"value":66235.4459,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees."}],"balance_after":98839,"source":{"system":"sec-edgar","filing":"0001453687-25-000035","document":"wk-form4_1736298282.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368725000035/wk-form4_1736298282.xml","form_type":"4"}},{"id":1310436,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":69762,"kind":"person","name":"Davis Blaine","position":1,"cik":"0001802188","reported_name":"Davis Blaine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-06T21:20:53.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":64600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029."}],"balance_after":64600,"derivative":{"exercise_price":16.93,"expiration_date":"2035-01-01","underlying":"Common  Stock","underlying_shares":64600},"source":{"system":"sec-edgar","filing":"0001453687-25-000025","document":"wk-form4_1736198446.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368725000025/wk-form4_1736198446.xml","form_type":"4"}},{"id":1310435,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":69762,"kind":"person","name":"Davis Blaine","position":1,"cik":"0001802188","reported_name":"Davis Blaine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common  Stock","published_at":"2025-01-06T21:20:53.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On April 4, 2024, the issuer effected a 1-for-30 reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."}],"balance_after":102800,"source":{"system":"sec-edgar","filing":"0001453687-25-000025","document":"wk-form4_1736198446.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368725000025/wk-form4_1736198446.xml","form_type":"4"}},{"id":1687677,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":69762,"kind":"person","name":"Davis Blaine","position":1,"cik":"0001802188","reported_name":"Davis Blaine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-04T22:08:29.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":3110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests as to 25% on January 2, 2025. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2028."}],"balance_after":3110000,"derivative":{"exercise_price":0.6552,"expiration_date":"2034-01-01","underlying":"Common  Stock","underlying_shares":3110000},"source":{"system":"sec-edgar","filing":"0001453687-24-000027","document":"wk-form4_1704406090.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368724000027/wk-form4_1704406090.xml","form_type":"4"}},{"id":1687676,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":69762,"kind":"person","name":"Davis Blaine","position":1,"cik":"0001802188","reported_name":"Davis Blaine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common  Stock","published_at":"2024-01-04T22:08:29.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":2424000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2025. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2028."}],"balance_after":2424000,"source":{"system":"sec-edgar","filing":"0001453687-24-000027","document":"wk-form4_1704406090.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368724000027/wk-form4_1704406090.xml","form_type":"4"}},{"id":1740610,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":69762,"kind":"person","name":"Davis Blaine","position":1,"cik":"0001802188","reported_name":"Davis Blaine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-11-15T22:26:51.000Z","date":"2023-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1250000,"price":0.79,"value":987500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option, which provided for vesting as to 25% on November 28, 2023 with the remainder of the underlying shares vesting in 36 equal monthly installments thereafter, was canceled in the merger (the \"Merger\") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc., in exchange for a cash payment of $987,500, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger."}],"balance_after":0,"derivative":{"exercise_price":1.27,"expiration_date":"2032-11-27","underlying":"Common Stock","underlying_shares":1250000},"source":{"system":"sec-edgar","filing":"0001453687-23-000089","document":"wk-form4_1700087199.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368723000089/wk-form4_1700087199.xml","form_type":"4"}},{"id":2101410,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":69762,"kind":"person","name":"Davis Blaine","position":1,"cik":"0001802188","reported_name":"Davis Blaine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-11-30T21:40:25.000Z","date":"2022-11-28","kind":"grant","acquired":true,"shares":1250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 25% on November 28, 2023. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter."}],"balance_after":1250000,"derivative":{"exercise_price":1.27,"expiration_date":"2032-11-27","underlying":"Common Stock","underlying_shares":1250000},"source":{"system":"sec-edgar","filing":"0001453687-22-000143","document":"wf-form4_166984440599363.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368722000143/wf-form4_166984440599363.xml","form_type":"4"}},{"id":2205122,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":69762,"kind":"person","name":"Davis Blaine","position":1,"cik":"0001802188","reported_name":"Davis Blaine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-07-19T20:31:18.000Z","date":"2022-07-15","kind":"tax_withholding","acquired":false,"shares":5081,"price":3.13,"value":15903.53,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 3, 2022."}],"balance_after":20662,"source":{"system":"sec-edgar","filing":"0001213900-22-040317","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390022040317/ownership.xml","form_type":"4"}},{"id":2443090,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":69762,"kind":"person","name":"Davis Blaine","position":1,"cik":"0001802188","reported_name":"Davis Blaine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-05T21:35:17.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":84800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares vest on the one year anniversary of January 3, 2022 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date."}],"balance_after":84800,"derivative":{"exercise_price":6.9,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":84800},"source":{"system":"sec-edgar","filing":"0001209191-22-001715","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1359931/000120919122001715/doc4.xml","form_type":"4"}},{"id":2443089,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":69762,"kind":"person","name":"Davis Blaine","position":1,"cik":"0001802188","reported_name":"Davis Blaine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-05T21:35:17.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":14100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock.  The RSUs vest in equal one-third installments on the first, second and third anniversaries of January 3, 2022."}],"balance_after":15581,"source":{"system":"sec-edgar","filing":"0001209191-22-001715","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359931/000120919122001715/doc4.xml","form_type":"4"}},{"id":2900445,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":69762,"kind":"person","name":"Davis Blaine","position":1,"cik":"0001802188","reported_name":"Davis Blaine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-21T20:05:45.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares vest on the one year anniversary of January 19, 2021 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date."}],"balance_after":75000,"derivative":{"exercise_price":19.82,"expiration_date":"2031-01-18","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-21-004653","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359931/000120919121004653/doc4.xml","form_type":"4"}},{"id":3023519,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":69762,"kind":"person","name":"Davis Blaine","position":1,"cik":"0001802188","reported_name":"Davis Blaine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-09-23T13:20:25.000Z","date":"2020-09-22","kind":"purchase","acquired":true,"shares":1481,"price":16.906,"value":25037.786,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.885 to $16.935, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price."}],"balance_after":1481,"source":{"system":"sec-edgar","filing":"0001209191-20-051631","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359931/000120919120051631/doc4.xml","form_type":"4"}},{"id":3279396,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":69762,"kind":"person","name":"Davis Blaine","position":1,"cik":"0001802188","reported_name":"Davis Blaine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-12T00:51:50.000Z","date":"2020-02-11","kind":"grant","acquired":true,"shares":94000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vesting upon Mr. Davis's completion of one year of service measured from the grant date and the balance of the shares vesting monthly thereafter for the next three years."}],"balance_after":94000,"derivative":{"exercise_price":37.3,"expiration_date":"2030-02-10","underlying":"Common Stock","underlying_shares":94000},"source":{"system":"sec-edgar","filing":"0001209191-20-008531","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359931/000120919120008531/doc4.xml","form_type":"4"}}]}